Renaissance Capital logo

Anbio Biotechnology Filed Terms, Nasdaq: NNNN

Germany-based developer of in vitro diagnostics products.

Industry: Health Care

Latest Trade: ()

First Day Return:

Return from IPO:

Industry: Health Care

Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs. Our comprehensive range of products encompasses solutions for various applications, including over-the-counter (OTC) utilization, point-of-care (POCT) settings, and laboratory applications. Our IVD products are designed to detect a wide range of biomarkers associated with critical medical domains. These domains encompass infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. By providing advanced diagnostic capabilities in these areas, we empower healthcare professionals to identify and monitor various conditions, facilitating timely intervention and patient care.
more less
IPO Data
IPO File Date 12/31/2024
Offer Price
Price Range $5.00 - $6.00
Offer Shares (mm) 1.6
Deal Size ($mm) $9
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date
Offer Price
Price Range $5.00 - $6.00
Offer Shares (mm) 1.6
Deal Size ($mm) $9
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
AC Sunshine Securities
Company Data
Headquarters Frankfurt am Main, Germany
Founded 2021
Employees at IPO 27
Website www.anbio.com

Anbio Biotechnology (NNNN) Performance